D. Boral Capital Reiterates “Buy” Rating for Can-Fite BioPharma (NYSE:CANF)

Can-Fite BioPharma (NYSE:CANF)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the stock.

CANF has been the subject of several other reports. StockNews.com began coverage on Can-Fite BioPharma in a report on Tuesday, February 11th. They issued a “sell” rating for the company. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th.

Can-Fite BioPharma Trading Up 0.3 %

Shares of NYSE:CANF traded up $0.01 on Tuesday, reaching $1.54. 144,462 shares of the company’s stock were exchanged, compared to its average volume of 97,427. Can-Fite BioPharma has a twelve month low of $1.29 and a twelve month high of $4.69. The company has a fifty day moving average of $1.54 and a 200-day moving average of $2.00. The company has a market capitalization of $5.43 million, a price-to-earnings ratio of -0.86 and a beta of 1.33.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers raised its stake in Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the period. Rhumbline Advisers owned 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.